A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma

Patients with asymptomatic (smoldering) multiple myeloma (AMM) have a high risk of transformation to active multiple myeloma (MM). Bisphosphonates such as zoledronic acid (ZLD) reduce skeletal events in MM and the immunomodulatory agent thalidomide (Thal) has proven effectiveness in active MM. We hy...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Witzig, TE, Laumann, KM, Lacy, MQ, Hayman, SR, Dispenzieri, A, Kumar, S, Reeder, CB, Roy, V, Lust, JA, Gertz, MA, Greipp, PR, Hassoun, H, Mandrekar, SJ, Rajkumar, SV
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2012
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC3912579/
https://ncbi.nlm.nih.gov/pubmed/22902362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2012.236
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन